leadf
logo-loader
AIM:OPTI FRA:OB3

OptiBiotix Health PLC

Receive alerts
Market:
AIM
Market Cap:
£48.37 m
Price
55.00 GBX
Change
-7.09%
52 weeks high
72.70
52 weeks low
23.20

In brief

OptiBiotix Health plc, which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The company's current areas of focus include obesity, cardiovascular health, and diabetes. 

Snapshot

  • Developer of technologies that modulate the human microbiome 
  • Targeting weight management and chronic lifestyle diseases
  • Existing deals expanded after Wellbiome launch

Insight Widest with the analysis, Proactive gives perspectives that others don't.

SkinBioTherapeutics targets the promising skin microbiome market

The life sciences firm studies how to enhance and reintroduce the good bacteria on the skin

on 14/7/20